Walleye Capital LLC Acquires Shares of 195,452 OraSure Technologies, Inc. (NASDAQ:OSUR)

Walleye Capital LLC purchased a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 195,452 shares of the medical instruments supplier's stock, valued at approximately $835,000. Walleye Capital LLC owned 0.26% of OraSure Technologies at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. AXA S.A. grew its stake in OraSure Technologies by 2.5% in the second quarter. AXA S.A. now owns 161,614 shares of the medical instruments supplier's stock valued at $688,000 after purchasing an additional 3,997 shares during the last quarter. SG Americas Securities LLC grew its stake in OraSure Technologies by 46.4% in the second quarter. SG Americas Securities LLC now owns 17,125 shares of the medical instruments supplier's stock valued at $73,000 after purchasing an additional 5,431 shares during the last quarter. Koss Olinger Consulting LLC grew its stake in OraSure Technologies by 9.4% in the third quarter. Koss Olinger Consulting LLC now owns 83,977 shares of the medical instruments supplier's stock valued at $359,000 after purchasing an additional 7,247 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in OraSure Technologies by 100.0% in the second quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier's stock valued at $102,000 after purchasing an additional 12,000 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of OraSure Technologies by 78.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier's stock worth $123,000 after purchasing an additional 12,604 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company's stock.

OraSure Technologies Stock Up 1.8 %

Shares of OSUR traded up $0.07 during trading hours on Friday, reaching $3.91. 773,295 shares of the company traded hands, compared to its average volume of 802,055. The business has a fifty day moving average price of $4.04 and a 200-day moving average price of $4.26. OraSure Technologies, Inc. has a 12-month low of $3.72 and a 12-month high of $8.45. The stock has a market capitalization of $291.65 million, a P/E ratio of 26.07 and a beta of 0.03.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The company had revenue of $39.92 million during the quarter, compared to analysts' expectations of $38.97 million. During the same quarter in the previous year, the firm posted $0.27 EPS. The firm's revenue was down 55.2% compared to the same quarter last year. As a group, research analysts predict that OraSure Technologies, Inc. will post -0.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised OraSure Technologies from a "hold" rating to a "buy" rating in a report on Friday, October 4th.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.